Critical Survey: Intersect ENT (XENT) and Its Rivals

Intersect ENT (NASDAQ: XENT) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its rivals? We will compare Intersect ENT to similar companies based on the strength of its valuation, institutional ownership, profitability, earnings, risk, analyst recommendations and dividends.

Volatility & Risk

Intersect ENT has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Intersect ENT’s rivals have a beta of 1.06, suggesting that their average share price is 6% more volatile than the S&P 500.


This table compares Intersect ENT and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intersect ENT -22.94% -17.60% -15.64%
Intersect ENT Competitors -127.09% -36.26% -10.19%

Earnings and Valuation

This table compares Intersect ENT and its rivals gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Intersect ENT $87.16 million -$19.71 million -39.79
Intersect ENT Competitors $827.23 million $159.49 million 36.37

Intersect ENT’s rivals have higher revenue and earnings than Intersect ENT. Intersect ENT is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

83.1% of Intersect ENT shares are owned by institutional investors. Comparatively, 63.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 13.7% of Intersect ENT shares are owned by insiders. Comparatively, 13.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Intersect ENT and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intersect ENT 0 2 8 0 2.80
Intersect ENT Competitors 171 1125 2464 89 2.64

Intersect ENT presently has a consensus target price of $27.11, indicating a potential downside of 2.65%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 9.41%. Given Intersect ENT’s rivals higher possible upside, analysts plainly believe Intersect ENT has less favorable growth aspects than its rivals.

About Intersect ENT

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

What are top analysts saying about Intersect ENT Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intersect ENT Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit